File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Mycophenolate mofetil as treatment for lupus nephritis

TitleMycophenolate mofetil as treatment for lupus nephritis
Authors
KeywordsLupus Nephritis
Mycophenolate Mofetil
Issue Date2004
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APL
Citation
Aplar Journal Of Rheumatology, 2004, v. 7 n. 3, p. 268-271 How to Cite?
AbstractAdvances in immunosuppressive treatment and supportive care over the past few decades have led to improved clinical outcomes in patients with severe lupus nephritis. The management of severe proliferative lupus nephritis can be divided into an initial induction phase followed by a prolonged maintenance phase. Combined use of corticosteroid and cyclophosphamide has been the standard induction therapy, although a significant proportion of patients develop treatment-related complications such as infection and gonadal failure. While there is general agreement on the immunosuppressive regimen for induction treatment, there is marked variation with regard to maintenance immunosuppressive regimens. The latter is consequent to a paucity of data, since a big sample size and prolonged follow-up is required for clinical studies that investigate maintenance treatment, in view of the marked heterogeneity in patient characteristics and individual differences in the propensity for relapse. Nevertheless, there is accumulating evidence that a combination of corticosteroid and mycophenolate mofetil can be adopted as effective and well-tolerated treatment both for induction and for long-term maintenance in lupus nephritis. Favourable long-term prognosis can be ensured provided that effective treatment can be instituted early, before irreversible renal parenchymal damage is established. ©Asia Pacific League of Associations for Rheumatology.
Persistent Identifierhttp://hdl.handle.net/10722/163559
ISSN
References

 

DC FieldValueLanguage
dc.contributor.authorChan, TMen_US
dc.date.accessioned2012-09-05T05:37:24Z-
dc.date.available2012-09-05T05:37:24Z-
dc.date.issued2004en_US
dc.identifier.citationAplar Journal Of Rheumatology, 2004, v. 7 n. 3, p. 268-271en_US
dc.identifier.issn0219-0494en_US
dc.identifier.urihttp://hdl.handle.net/10722/163559-
dc.description.abstractAdvances in immunosuppressive treatment and supportive care over the past few decades have led to improved clinical outcomes in patients with severe lupus nephritis. The management of severe proliferative lupus nephritis can be divided into an initial induction phase followed by a prolonged maintenance phase. Combined use of corticosteroid and cyclophosphamide has been the standard induction therapy, although a significant proportion of patients develop treatment-related complications such as infection and gonadal failure. While there is general agreement on the immunosuppressive regimen for induction treatment, there is marked variation with regard to maintenance immunosuppressive regimens. The latter is consequent to a paucity of data, since a big sample size and prolonged follow-up is required for clinical studies that investigate maintenance treatment, in view of the marked heterogeneity in patient characteristics and individual differences in the propensity for relapse. Nevertheless, there is accumulating evidence that a combination of corticosteroid and mycophenolate mofetil can be adopted as effective and well-tolerated treatment both for induction and for long-term maintenance in lupus nephritis. Favourable long-term prognosis can be ensured provided that effective treatment can be instituted early, before irreversible renal parenchymal damage is established. ©Asia Pacific League of Associations for Rheumatology.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APLen_US
dc.relation.ispartofAPLAR Journal of Rheumatologyen_US
dc.subjectLupus Nephritisen_US
dc.subjectMycophenolate Mofetilen_US
dc.titleMycophenolate mofetil as treatment for lupus nephritisen_US
dc.typeConference_Paperen_US
dc.identifier.emailChan, TM:dtmchan@hku.hken_US
dc.identifier.authorityChan, TM=rp00394en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1479-8077.2004.00101.xen_US
dc.identifier.scopuseid_2-s2.0-23444453875en_US
dc.identifier.hkuros132105-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-23444453875&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume7en_US
dc.identifier.issue3en_US
dc.identifier.spage268en_US
dc.identifier.epage271en_US
dc.publisher.placeAustraliaen_US
dc.identifier.scopusauthoridChan, TM=7402687700en_US
dc.identifier.citeulike66223-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats